Trial Profile
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms PrEP
- 02 Nov 2022 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science
- 29 Apr 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2021.